JCEM: Vitamin B12 and folic acid concentrations in newly developed type 2 diabetes patients and the effects of metformin treatment

Vitamin B12 and folic acid deficiency are associated not only with blood, nerves and cardiovascular disease, but also with insulin resistanceMetformin reduces the concentration of vitamin B12 and folic acidRecently, the authoritative journal of endocrine and metabolic diseases published a research article in the Journal of Clinical Endocrinology and Metabolism, which looked at the effects of short-term metformin treatment for new type 2 diabetes (i) on serum total anti-cobalt (holoTC) and folic acid, as well as (ii) its relationship with insulin sensitivitythe cross-sectional analysis included patients with metformin in German diabetes studies who were treated with met, n-12381 men, 53 to 12 years of age, or non-drug therapy (NPT, n-12677 men, 54-11 years of age) in patients with the disease (known course of disease for 12 months)The main outcome indicators of the study were holoTC (ELISA), cobalamin and folic acid (electrochemical luminescence), fasting (HOMA-B, HOMA-IR), intravenous glucose tolerance test (IVGTT), beta cell function and systemic insulin sensitivity detected in the hyperinsulinemia clamp testthe holoTC (105.4,128.3) vs97 ,79.7, 121.9 pmol/L) and folic acid (13.4,9.3, 19.3) vs12.7 .9.3, 22.0?nmol/L concentration) are similarIn general, holoTC is not associated with fasting, glucose-stimulating beta cell function and insulin-stimulating glucose utilizationCobalamin measurements yielded similar resultsIn the NPT group, not the MET group, folate levels were negatively correlated with HOMA-IR (r-0.239, P-0.007)After adjusting age, BMI, and gender, folic acid levels in the entire queue and each group were not related to insulin sensitivity and insulin secretion, respectivelyit can be seen that metformin does not affect the concentration of holoTC and folic acid in the blood of newly developed type 2 diabeticsTherefore, monitoring of vitamin B12 and folic acid is not necessary for at least the first 6 months after diagnosis or the first use of metformin